A Study to Measure Needle Bending and Changes in Prostate Shape During a Prostate Seed Implant

Prostate Cancer Clinical Trial

Official title:

Quantifying Needle Deflection and Tissue Deformation in Transperineal Interstitial Permanent Prostate Brachytherapy: A Basis for Development of Next-Generation Implant Technique

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01437085
• Other study ID #: 25837
• Status: Active, not recruiting
• Phase: N/A
• First received: September 19, 2011
• Last updated: January 23, 2017
• Start date: October 2011
• Est. completion date: August 2017

Study information

• Verified date: January 2017
• Source: AHS Cancer Control Alberta
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Prostate brachytherapy is an effective treatment option for men with localized prostate cancer, with excellent cure rates and a favorable toxicity profile. With the current needle insertion technique, seed placement inaccuracy is primarily caused by needle deflection and soft tissue deformation, which both occur during the brachytherapy operation. This study will accrue 20 patients undergoing prostate brachytherapy implants and acquire a series of ultrasound images, video clips and one CT scan.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 25
• Est. completion date: August 2017
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Prostate cancer

• Treated with prostate brachytherapy at the Cross Cancer Institute

• Low and intermediate risk prostate cancer

• ambulatory patients

• stable medical condition

• Over 18 years of age

• Capable of giving informed consent

Exclusion Criteria:

• Any hormonal therapy

Related Conditions & MeSH terms

• Prostate Cancer

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
AHS Cancer Control Alberta

Country where clinical trial is conducted

Canada,